From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
PSMA-azide is a prostate-specific membrane antigen (PSMA) ligand. PSMA-azide inhibits PSMA-dependent NAAG (N-acetylaspartylglutamic acid) hydrolysis, with an IC50 of 9 nM and a Ki of 1 nM. PSMA-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .
PSMA targeting peptide TFA (PSMA-1 TFA) is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells .
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
PSMA precursor-1 is a precursor in the synthesis of prostate-specific membrane antigen (PSMA) ligands and fluorescent probes that have been used in the detection of PSMA in LNCaP and PC3 cells .
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .
PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope 225Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .
PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer .
PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .
PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ 68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([ 68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA).PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .
PSMA1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Psma4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA7 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Psma3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Psma3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA8 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA4 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA5 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Psma4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA3 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA6 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
Biotin-NH-PSMA-617 is a biotin-tagged PSMA-617. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells .
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .
Lu-AAZTA-NI-PSMA-093 enhances tumor uptake and retention by combining a hypoxia-sensitive nitroimidazole (NI) moiety with a targeting moiety to PSMA. Lu-AAZTA-NI-PSMA-093 can be used in prostate cancer .
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .
CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Tc-BQ0413 exhibits binds specifically to prostate-specific membrane antigen (PSMA) with good affinity. Tc-BQ0413 can be used as a single-photon emission computed tomography (SPECT) imaging agent, when labeled with technetium-99m .
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
Glu-urea-Glu-NHS ester (compound 21) is an activated N-hydroxysuccinamide (NHS) ester of Glu-urea-Glu which can be used as a pharmacophore for linking with prostate specific membrane antigen (PSMA) inhibitors .
tert-Butyl-DCL is a small molecule PSMAM inhibitor with anticancer activity that targets prostate-specific membrane antigen (PSMA). tert-Butyl-DCL is also an effective bioimaging agent that has high selectivity and affinity, allowing it to target and highlight specific receptors on the surface of tumor cells .
Piflufolastat (DCFPYL) can be used to the preparation of piflufolastat F 18 (DCFPyL F-18). piflufolastat F 18. Piflufolastat F-18 is an 18F-labelled diagnostic imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) that targets prostate-specific membrane antigen (PSMA) .
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the pharmacokinetic properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound .
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .
2-MPPA (Standard) is the analytical standard of 2-MPPA. This product is intended for research and analytical applications. 2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM .
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
CTT2274 is a prodrug of MMAE (HY-15162). CTT2274 is composed of a prostate-specific membrane antigen (PSMA)-binding scaffold, a biphenyl motif, a pH-sensitive phosphoramidate linker, and MMAE payload. CTT2274 shows selective binding to PSMA and delivers MMAE. CTT2274 inhibits prostate cancer .
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Bone-1064 is a EuK-based PSMA tetramer bone probe for high-contrast visualization of bone in surrounding tissue. Bone-1064 specifically binds hydroxyapatite in bone tissue and can be used for NIR-II fluorescence imaging in animal models .
BQ0413 exhibits good affinity to PSMA with a KD of 89 pM. BQ0413 exhibits good uptake and internalization property with an internalization rate of 44% in PC3-pip cell. BQ0413 can be used as tumor imaging agent when labeled with 99mTc .
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( 131I labeled) as an imaging probe to indicate tumor progression. And 131I-MIP-1095 showed higher renal uptake in mice .
Immunoproteasome activator 1 (compound A) is a selective immunoproteasome activator that increases the presentation of individual MHC-I–bound peptides by over 100-fold. Immunoproteasome activator 1 binds to the proteasome structural subunit PSMA1 and promotes the association of the proteasome activator PA28α/β (PSME1/PSME2) with immunoproteasomes .
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer (room temperature, 2 h, pH 7-7.5) to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
tert-Butyl-DCL is a small molecule PSMAM inhibitor with anticancer activity that targets prostate-specific membrane antigen (PSMA). tert-Butyl-DCL is also an effective bioimaging agent that has high selectivity and affinity, allowing it to target and highlight specific receptors on the surface of tumor cells .
PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
PSMA targeting peptide TFA (PSMA-1 TFA) is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells .
PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ 68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([ 68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .
CBP-1018 is a PDC (peptide drug conjugate) consisting of a dual targeting FRα/prostate-specific membrane antigen (PSMA) ligand (blue part) coupled to Monomethyl auristatin E (HY-15162) (red part) via a linker (HY-78738) (black part). CBP-1018 is expected to be used in breast cancer research .
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
PSMA Protein, a multifunctional enzyme, acts as a folate hydrolase and NAALADase with a preference for tri-alpha-glutamate peptides. In the intestine, it aids folate uptake for metabolic processes. In the brain, PSMA modulates neurotransmission by hydrolyzing NAAG, releasing glutamate. It also shows dipeptidyl-peptidase IV type activity and effectively cleaves Gly-Pro-AMC, highlighting its versatile enzymatic functions. PSMA Protein, Mouse (HEK293, His) is the recombinant mouse-derived PSMA protein, expressed by HEK293 , with N-6*His labeled tag.
PSMA Protein is a type II transmembrane glycoprotein highly expressed on the surface of prostate cancer cells. PSMA Protein hydrolyzes extracellular polyglutamic acid folate into monoglutamic acid folate through folate hydrolase activity, improving the uptake efficiency of folate by tumor cells to support proliferation; and participates in neuropeptide metabolism through NAALADase activity. PSMA Protein, Human (HEK293, His, solution) is a recombinant PSMA protein expressed by HEK293 with an N-6*His tag.
PSMA3 is a protein involved in protein degradation. PSMA3 Protein, Human (His) is the recombinant human-derived PSMA3 protein, expressed by E. coli , with N-His labeled tag.
PSMA protein, with a preference for tri-alpha-glutamate peptides, acts as a folate hydrolase and NAALADase enzyme. It uptakes folate in the intestines, modulates excitatory neurotransmission by hydrolyzing NAAG to release glutamate in the brain, and exhibits dipeptidyl-peptidase IV type activity by cleaving Gly-Pro-AMC in vitro. PSMA Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived PSMA protein, expressed by HEK293 , with N-6*His labeled tag.
PSMA protein, with a preference for tri-alpha-glutamate peptides, acts as a folate hydrolase and NAALADase enzyme. It uptakes folate in the intestines, modulates excitatory neurotransmission by hydrolyzing NAAG to release glutamate in the brain, and exhibits dipeptidyl-peptidase IV type activity by cleaving Gly-Pro-AMC in vitro. PSMA Protein, Human (HEK293, N-His) is the recombinant human-derived PSMA protein, expressed by HEK293 , with N-6*His labeled tag.
The PSMA protein is a multifunctional enzyme with folate hydrolase and NAALADase activities and a preference for tri-alpha-glutamic acid peptides. It absorbs folate in the intestines, aids in important metabolic processes, and modulates excitatory neurotransmission in the brain by hydrolyzing NAAG to release glutamate. PSMA Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived PSMA protein, expressed by HEK293 , with N-His labeled tag.
PSMA protein is an important peptidase M28 family member in the M28B subfamily and plays an important role as a peptidase involved in the hydrolysis of peptide bonds. PSMA may share conserved features with related proteins, emphasizing its role in cellular processes related to peptide metabolism. PSMA Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived PSMA protein, expressed by HEK293 , with N-His labeled tag.
PSMA Antibody (YA1764) is a non-conjugated IgG antibody, targeting PSMA, with a predicted molecular weight of 84 kDa (observed band size: 100 kDa). PSMA Antibody (YA1764) can be used for WB experiment in human background.
PSMA1 Antibody (YA2301) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2301), targeting PSMA1, with a predicted molecular weight of 30 kDa (observed band size: 30 kDa). PSMA1 Antibody (YA2301) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.
PSMA3 Antibody (YA2386) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2386), targeting PSMA3, with a predicted molecular weight of 28 kDa (observed band size: 28 kDa). PSMA3 Antibody (YA2386) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
PSMA2 Antibody (YA2384) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2384), targeting PSMA2, with a predicted molecular weight of 26 kDa (observed band size: 26 kDa). PSMA2 Antibody (YA2384) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.
PSMA4 Antibody (YA1765) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1765), targeting PSMA4, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). PSMA4 Antibody (YA1765) can be used for WB, IHC-F, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
Proteasome alpha 2 Antibody (YA1744) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1744), targeting Proteasome alpha 2, with a predicted molecular weight of 26 kDa (observed band size: 26 kDa). Proteasome alpha 2 Antibody (YA1744) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human, mouse, rat background.
PSMA-azide is a prostate-specific membrane antigen (PSMA) ligand. PSMA-azide inhibits PSMA-dependent NAAG (N-acetylaspartylglutamic acid) hydrolysis, with an IC50 of 9 nM and a Ki of 1 nM. PSMA-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups .
PSMA1 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Psma4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA7 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Psma3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA2 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Psma3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA8 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA4 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA5 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Psma4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Psma4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA3 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
PSMA6 Human Pre-designed siRNA Set A contains three designed siRNAs for PSMA6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
